Armata Pharmaceuticals (ARMP) Income from Continuing Operations (2013 - 2026)

Armata Pharmaceuticals has disclosed Income from Continuing Operations across 14 years of filings, most recently posting 14344000.0 for Q1 2026.

• Income from Continuing Operations for Q1 2026 came in at 14344000.0, down 21.63% year-over-year; the trailing twelve-month figure through Mar 2026 was 55775000.0 (down 5.83% YoY), and the FY2025 annual result was 53224000.0, changed 0.09% from the prior year.
• Income from Continuing Operations came in at 14344000.0 for Q1 2026 at Armata Pharmaceuticals, up from 18657000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 8614000.0 in Q3 2022 to a low of 18657000.0 in Q4 2025.
• The 5-year median for Income from Continuing Operations is 11465000.0 (2023), against an average of 11807470.59.
• Across the five-year window, Income from Continuing Operations sank 70.56% in 2022 and rose 26.08% in 2025, its largest moves.
• Armata Pharmaceuticals' Income from Continuing Operations stood at 10314000.0 in 2022, then dropped by 6.27% to 10961000.0 in 2023, then declined by 26.07% to 13819000.0 in 2024, then plunged by 35.01% to 18657000.0 in 2025, then gained by 23.12% to 14344000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 14344000.0 (Q1 2026), 18657000.0 (Q4 2025), and 12122000.0 (Q3 2025), per Business Quant data.